Skip to main content

Advertisement

SpringerLink
Log in

Multiple Drug Resistance Mechanisms in Cancer

  • Review
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

Multiple drug resistance (multidrug resistance; MDR), a phenomenon whereby human tumours that acquire resistance to one type of therapy are found to be resistant to several other drugs that are often quite different in both structure and mode of action, has been recognised clinically for several decades. An important advance in our understanding of MDR came with the identification of P-glycoprotein and other related transporters that were expressed in some cancer cells and could recognise and catalyse the efflux of diverse anticancer drugs from cells. A second advance came from an understanding of the mechanism of programmed cell death or apoptosis, leading to MDR mediated by increased to resistance to anticancer drug-induced apoptosis. A third advance came with the finding that the proliferation of human tumours was driven by a small population of self-renewing tumour cells, focussing attention on the MDR properties of these so-called tumour stem cells rather than on the cells that comprised the majority of the tumour population. A fourth advance was the delineation of features of the tumour microenvironment, including immunosuppression, which essentially provided tumour stem cells with an MDR phenotype. Most published work on the overcoming of MDR has concentrated on inhibition of drug transporters but the complexity of mechanisms contributing demands a broad strategy for the development of methods to overcome MDR in a clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bolhuis, H., Van Veen, H. W., Poolman, B., Driessen, A. J., & Konings, W. N. (1997). Mechanisms of multidrug transporters. FEMS Microbiology Reviews, 21, 55–84.

    Article  CAS  Google Scholar 

  2. Kawase, M., & Motohashi, N. (2003). New multidrug resistance reversal agents. Current Drug Targets, 4, 31–43.

    Article  CAS  Google Scholar 

  3. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219–234.

    Article  CAS  Google Scholar 

  4. Ozben, T. (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Letters, 580, 2903–2909.

    Article  CAS  Google Scholar 

  5. Dubikovskaya, E. A., Thorne, S. H., Pillow, T. H., Contag, C. H., & Wender, P. A. (2008). Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proceedings of the National Academy of Sciences of the United States of America, 105, 12128–12133.

    Article  CAS  Google Scholar 

  6. Baguley, B. C. (2010). Multidrug resistance in cancer. Methods in Molecular Biology, 596, 1–14.

    Article  CAS  Google Scholar 

  7. Baguley, B. C. (2002). Novel strategies for overcoming multidrug resistance in cancer. BioDrugs, 16, 97–103.

    Article  CAS  Google Scholar 

  8. Baguley, B. C., & Marshall, E. S. (2008). The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs. Expert Opinion on Drug Discovery, 3, 153–161.

    Article  CAS  Google Scholar 

  9. Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008). The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research, 14, 2519–2526.

    Article  CAS  Google Scholar 

  10. Parmar, K., Mauch, P., Vergilio, J., Sackstein, R., & Down, J. D. (2007). Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 104, 5431–5436.

    Article  CAS  Google Scholar 

  11. Huls, M., Russel, F. G., & Masereeuw, R. (2009). The role of ABC transporters in tissue defense and organ regeneration. Journal of Pharmacology and Experimental Therapeutics, 328, 3–9.

    Article  CAS  Google Scholar 

  12. Turco, M. C., Romano, M. F., Petrella, A., Bisogni, R., Tassone, P., & Venuta, S. (2004). NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia, 18, 11–17.

    Article  CAS  Google Scholar 

  13. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research, 11, 6713–6721.

    Article  CAS  Google Scholar 

  14. Finlay, G. J., & Baguley, B. C. (2000). Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemotherapy and Pharmacology, 45, 417–422.

    Article  CAS  Google Scholar 

  15. Hicks, K. O., Pruijn, F. B., Baguley, B. C., & Wilson, W. R. (2001). Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): Diffusion and metabolism in multicellular layers of tumor cells. Journal of Pharmacology and Experimental Therapeutics, 297, 1088–1098.

    CAS  Google Scholar 

  16. Nakagawa, T., Inoue, Y., Kodama, H., Yamazaki, H., Kawai, K., Suemizu, H., et al. (2008). Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncology Reports, 20, 265–270.

    CAS  Google Scholar 

  17. Chen, K. G., Valencia, J. C., Lai, B., Zhang, G., Paterson, J. K., Rouzaud, F., et al. (2006). Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proceedings of the National Academy of Sciences of the United States of America, 103, 9903–9907.

    Article  CAS  Google Scholar 

  18. Ling, V. (1997). Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemotherapy and Pharmacology, 40, S3–S8.

    Article  CAS  Google Scholar 

  19. Gillet, J. P., Efferth, T., & Remacle, J. (2007). Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochimica et Biophysica Acta, 1775, 237–262.

    CAS  Google Scholar 

  20. Ejendal, K. F., & Hrycyna, C. A. (2002). Multidrug resistance and cancer: The role of the human ABC transporter ABCG2. Current Protein & Peptide Science, 3, 503–511.

    Article  CAS  Google Scholar 

  21. Sarkadi, B., Ozvegy-Laczka, C., Nemet, K., & Varadi, A. (2004). ABCG2—a transporter for all seasons. FEBS Letters, 567, 116–120.

    Article  CAS  Google Scholar 

  22. Loebinger, M. R., Giangreco, A., Groot, K. R., Prichard, L., Allen, K., Simpson, C., et al. (2008). Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. British Journal of Cancer, 98, 380–387.

    Article  CAS  Google Scholar 

  23. Hadnagy, A., Gaboury, L., Beaulieu, R., & Balicki, D. (2006). SP analysis may be used to identify cancer stem cell populations. Experimental Cell Research, 312, 3701–3710.

    Article  CAS  Google Scholar 

  24. Keshet, G. I., Goldstein, I., Itzhaki, O., Cesarkas, K., Shenhav, L., Yakirevitch, A., et al. (2008). MDR1 expression identifies human melanoma stem cells. Biochemical and Biophysical Research Communications, 368, 930–936.

    Article  CAS  Google Scholar 

  25. Gandhi, L., Harding, M. W., Neubauer, M., Langer, C. J., Moore, M., Ross, H. J., et al. (2007). A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer, 109, 924–932.

    Article  CAS  Google Scholar 

  26. Abraham, J., Edgerly, M., Wilson, R., Chen, C., Rutt, A., Bakke, S., et al. (2009). A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clinical Cancer Research, 15, 3574–3582.

    Article  CAS  Google Scholar 

  27. Ruff, P., Vorobiof, D. A., Jordaan, J. P., Demetriou, G. S., Moodley, S. D., Nosworthy, A. L., et al. (2009). A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemotherapy and Pharmacology, 64, 763–768.

    Article  CAS  Google Scholar 

  28. Robbie, M. A., Baguley, B. C., Denny, W. A., Gavin, J. B., & Wilson, W. R. (1988). Mechanism of resistance of noncycling mammalian cells to 4′-(9- acridinylamino)methanesulfon-m-anisidide: Comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures. Cancer Research, 48, 310–319.

    CAS  Google Scholar 

  29. Haldane, A., Finlay, G. J., Hay, M. P., Denny, W. A., & Baguley, B. C. (1999). Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Anti-Cancer Drug Design, 14, 275–280.

    CAS  Google Scholar 

  30. Davey, R. A., Su, G. M., Hargrave, R. M., Harvie, R. M., Baguley, B. C., & Davey, M. W. (1997). The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemotherapy and Pharmacology, 39, 424–430.

    Article  CAS  Google Scholar 

  31. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.

    Article  CAS  Google Scholar 

  32. Sharma, S. V., Gajowniczek, P., Way, I. P., Lee, D. Y., Jiang, J., Yuza, Y., et al. (2006). A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell, 10, 425–435.

    Article  CAS  Google Scholar 

  33. Olson, J. M., & Hallahan, A. R. (2004). p38 MAP kinase: A convergence point in cancer therapy. Trends in Molecular Medicine, 10, 125–129.

    Article  CAS  Google Scholar 

  34. Danial, N. N. (2007). BCL-2 family proteins: Critical checkpoints of apoptotic cell death. Clinical Cancer Research, 13, 7254–7263.

    Article  CAS  Google Scholar 

  35. Forte, M., & Bernardi, P. (2006). The permeability transition and BCL-2 family proteins in apoptosis: Co-conspirators or independent agents? Cell Death and Differentiation, 13, 1287–1290.

    Article  CAS  Google Scholar 

  36. Pham, C. G., Bubici, C., Zazzeroni, F., Knabb, J. R., Papa, S., Kuntzen, C., et al. (2007). Upregulation of twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Molecular and Cellular Biology, 27, 3920–3935.

    Article  CAS  Google Scholar 

  37. Osford, S. M., Dallman, C. L., Johnson, P. W., Ganesan, A., & Packham, G. (2004). Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Current Medicinal Chemistry, 11, 1031–1039.

    Article  Google Scholar 

  38. Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science, 286, 2507–2510.

    Article  CAS  Google Scholar 

  39. Sebolt-Leopold, J. S. (2004). MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Current Pharmaceutical Design, 10, 1907–1914.

    Article  CAS  Google Scholar 

  40. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Research, 68, 8022–8030.

    Article  CAS  Google Scholar 

  41. Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 104, 19512–19517.

    Article  CAS  Google Scholar 

  42. Nakanishi, C., & Toi, M. (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nature Reviews Cancer, 5, 297–309.

    Article  CAS  Google Scholar 

  43. Wang, W., McLeod, H. L., & Cassidy, J. (2003). Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer, 104, 504–511.

    Article  CAS  Google Scholar 

  44. Bunney, T. D., & Katan, M. (2010). Phosphoinositide signalling in cancer: Beyond PI3K and PTEN. Nature Reviews Cancer, 10, 342–352.

    Article  CAS  Google Scholar 

  45. Cleary, J. M., & Shapiro, G. I. (2010). Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Current Oncology Reports, 12, 87–94.

    Article  Google Scholar 

  46. Hersey, P., Zhuang, L., & Zhang, X. D. (2006). Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. International Review of Cytology, 251, 131–158.

    Article  CAS  Google Scholar 

  47. Saini, V., & Shoemaker, R. H. (2010). Potential for therapeutic targeting of tumor stem cells. Cancer Science, 101, 16–21.

    Article  CAS  Google Scholar 

  48. Li, L., & Clevers, H. (2010). Coexistence of quiescent and active adult stem cells in mammals. Science, 327, 542–545.

    Article  CAS  Google Scholar 

  49. Massague, J. (2008). TGFbeta in cancer. Cell, 134, 215–230.

    Article  CAS  Google Scholar 

  50. Vermeulen, L., De Sousa, E. M., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., et al. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12, 468–476.

    Article  CAS  Google Scholar 

  51. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 141, 583–594.

    Article  CAS  Google Scholar 

  52. MacKie, R. M., Reid, R., & Junor, B. (2003). Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. New England Journal of Medicine, 348, 567–568.

    Article  Google Scholar 

  53. Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7, 834–846.

    Article  CAS  Google Scholar 

  54. Demicheli, R., Retsky, M. W., Hrushesky, W. J., & Baum, M. (2007). Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: Learning from failures. Nature Clinical Practice Oncology, 4, 699–710.

    Article  Google Scholar 

  55. Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450, 903–907.

    Article  CAS  Google Scholar 

  56. Kortylewski, M., Komyod, W., Kauffmann, M. E., Bosserhoff, A., Heinrich, P. C., & Behrmann, I. (2004). Interferon-gamma-mediated growth regulation of melanoma cells: Involvement of STAT1-dependent and STAT1-independent signals. Journal of Investigative Dermatology, 122, 414–422.

    Article  CAS  Google Scholar 

  57. Muller-Hermelink, N., Braumuller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., et al. (2008). TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell, 13, 507–518.

    Article  Google Scholar 

  58. Kramer, A., Lukas, J., & Bartek, J. (2004). Checking out the centrosome. Cell Cycle, 3, 1390–1393.

    CAS  Google Scholar 

  59. McDermott, K. M., Zhang, J., Holst, C. R., Kozakiewicz, B. K., Singla, V., & Tlsty, T. D. (2006). p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biology, 4, e51.

    Article  Google Scholar 

  60. Loeb, L. A., Bielas, J. H., & Beckman, R. A. (2008). Cancers exhibit a mutator phenotype: Clinical implications. Cancer Research, 68, 3551–3557.

    Article  CAS  Google Scholar 

  61. Leung, E., Kannan, N., Krissansen, G. W., Findlay, M. P., & Baguley, B. C. (2010). MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biology & Therapy, 9(9), 717–724.

    Google Scholar 

  62. Kuilman, T., Michaloglou, C., Vredeveld, L. C., Douma, S., van Doorn, R., Desmet, C. J., et al. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 133, 1019–1031.

    Article  CAS  Google Scholar 

  63. Acosta, J. C., O’Loghlen, A., Banito, A., Raguz, S., & Gil, J. (2008). Control of senescence by CXCR2 and its ligands. Cell Cycle, 7, 2956–2959.

    CAS  Google Scholar 

  64. Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001). A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology, 2, 293–299.

    Article  CAS  Google Scholar 

  65. Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008). Immunological aspects of cancer chemotherapy. Nature Reviews Immunology, 8, 59–73.

    Article  CAS  Google Scholar 

  66. Fonseca, C., & Dranoff, G. (2008). Capitalizing on the immunogenicity of dying tumor cells. Clinical Cancer Research, 14, 1603–1608.

    Article  CAS  Google Scholar 

  67. Baguley, B. C. (2006). Tumor stem cell niches: A new functional framework for the action of anticancer drugs. Recent Patents on Anti-Cancer Drug Discovery, 1, 121–127.

    Article  CAS  Google Scholar 

  68. Chen, R., Alvero, A. B., Silasi, D. A., Steffensen, K. D., & Mor, G. (2008). Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. Oncogene, 27, 225–233.

    Article  CAS  Google Scholar 

  69. Hicks, A. M., Riedlinger, G., Willingham, M. C., Alexander-Miller, M. A., Kap-Herr, C., Pettenati, M. J., et al. (2006). Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings of the National Academy of Sciences of the United States of America, 103, 7753–7758.

    Article  CAS  Google Scholar 

  70. Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., et al. (2008). The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death and Differentiation, 15, 1499–1509.

    Article  CAS  Google Scholar 

  71. Baguley, B. C., & Marshall, E. S. (2004). In vitro modelling of human tumour behaviour in drug discovery programmes. European Journal of Cancer, 40, 794–801.

    Article  CAS  Google Scholar 

  72. Sotiriou, C., & Piccart, M. J. (2007). Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nature Reviews Cancer, 7, 545–553.

    Article  CAS  Google Scholar 

  73. Samson, D. J., Seidenfeld, J., Ziegler, K., & Aronson, N. (2004). Chemotherapy sensitivity and resistance assays: A systematic review. Journal of Clinical Oncology, 22, 3618–3630.

    Article  CAS  Google Scholar 

  74. Claus, R., & Lubbert, M. (2003). Epigenetic targets in hematopoietic malignancies. Oncogene, 22, 6489–6496.

    Article  CAS  Google Scholar 

  75. Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., et al. (2003). Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science, 300, 1155–1159.

    Article  CAS  Google Scholar 

  76. Vit, J. P., & Rosselli, F. (2003). Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene, 22, 8645–8652.

    Article  CAS  Google Scholar 

  77. Duff, M. D., Mestre, J., Maddali, S., Yan, Z. P., Stapleton, P., & Daly, J. M. (2007). Analysis of gene expression in the tumor-associated macrophage. Journal of Surgical Research, 142, 119–128.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand

    Bruce C. Baguley

Authors
  1. Bruce C. Baguley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce C. Baguley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baguley, B.C. Multiple Drug Resistance Mechanisms in Cancer. Mol Biotechnol 46, 308–316 (2010). https://doi.org/10.1007/s12033-010-9321-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12033-010-9321-2

Keywords

Search

Navigation